Diagnosis and Management of Interstitial Lung Disease

Initial Diagnostic Evaluation

• A multidisciplinary approach is the method of choice for ILD diagnosis and severity evaluation, integrating high-resolution computed tomography (HRCT), pulmonary function tests (PFTs), and symptom evaluation with pulmonary, rheumatology, and radiology expertise 1, 2
• Evaluate for respiratory symptoms such as dyspnea on exertion and non-productive cough, though these may be absent in up to 90% of early ILD cases 3
• Assess for finger clubbing, weight loss, and auscultate for fine crackles (Velcro-crackles), which have moderate sensitivity for early ILD detection 2
• Document detailed environmental and occupational exposure history to identify potential causes of hypersensitivity pneumonitis 4
• Evaluate for signs and symptoms of connective tissue diseases (CTDs) as they commonly associate with ILD 4
• Complete blood count with differential, C-reactive protein, serum creatinine, transaminases, gamma-glutamyltransferase, and alkaline phosphatases should be performed 4
• Autoimmune serologies including anti-nuclear antibodies, anti-citrullinated cyclic peptide antibodies, and rheumatoid factor should be tested 4
• HRCT is the gold standard for ILD diagnosis and should be performed in all patients with suspected ILD 1, 2
• HRCT patterns help identify specific ILD types, such as usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP) 1
• Spirometry to identify restrictive pattern (decreased FVC) should be performed 1, 2
• Total lung capacity (TLC) to confirm restriction should be measured 2
• Diffusion capacity (DLCO) to assess gas exchange impairment should be tested 1, 2
• 6-minute walk test to evaluate exercise capacity and oxygen desaturation should be performed 2

Tissue Diagnosis

• When HRCT and clinical findings are insufficient for definitive diagnosis, consider lung biopsy 5
• Transbronchial lung cryobiopsy (TBLC) is suggested as first-line biopsy method for patients who need histopathological confirmation 5
• TBLC provides larger samples without crush artifacts compared to traditional transbronchial lung biopsy 5
• TBLC has lower complication rates than surgical lung biopsy (SLB) 5
• Bronchoalveolar lavage (BAL) for cellular analysis can provide diagnostic clues, such as lymphocyte count >25% suggesting granulomatous disease or cellular NSIP 6

Multidisciplinary Discussion

• Multidisciplinary discussion (MDD) involving pulmonologists, radiologists, and pathologists is mandatory for optimal diagnostic yield 7, 1
• MDD should integrate clinical, radiological, and pathological findings to establish a final diagnosis 7

Management of ILD

• For most CTD-ILD patients (except SSc-ILD), consider mycophenolate, azathioprine, rituximab, or cyclophosphamide as first-line treatment options 8
• Avoid glucocorticoids as first-line treatment in SSc-ILD (strong recommendation against) 8
• Tocilizumab is conditionally recommended as first-line option for SSc-ILD and mixed connective tissue disease-ILD 8
• Nintedanib is conditionally recommended for SSc-ILD 8
• JAK inhibitors and calcineurin inhibitors are conditionally recommended for idiopathic inflammatory myopathy-ILD 8

Follow-up and Monitoring

• Regular clinical assessment for symptoms progression should be performed 1, 2
• Serial PFTs (spirometry and DLCO) at 3-6 month intervals initially, then annually if stable should be performed 1, 2
• Follow-up HRCT based on clinical and PFT changes should be performed 1
• Progressive pulmonary fibrosis is defined by at least two of: worsening respiratory symptoms, physiological evidence of progression on PFTs, and radiological evidence of progression on chest CT 2

Interstitial Lung Disease Diagnosis and Management

Clinical Examination Findings

• Digital clubbing is present in 25-50% of patients with idiopathic pulmonary fibrosis (IPF), though it may be absent in early disease, according to the American Thoracic Society 9
• Assess for cyanosis, which appears in late-stage disease and indicates severe gas exchange impairment, as noted by the American Thoracic Society 9
• Note weight loss and signs of malaise, though fever is rare and suggests alternative diagnosis, as reported by the American Thoracic Society 9
• Palpate for signs of right ventricular heave in advanced disease with cor pulmonale, as indicated by the American Thoracic Society 9
• Check for peripheral edema indicating right heart failure in late phases, according to the American Thoracic Society 9
• Percussion typically reveals normal resonance in early ILD, as fibrosis does not significantly alter percussion notes, as stated by the American College of Rheumatology 10
• Altered lung resonance may occur with extensive fibrosis or complications like pneumothorax, as noted by the American College of Rheumatology 10
• Fine, dry, "Velcro-type" end-inspiratory crackles are the hallmark finding, detected in more than 80% of IPF patients, according to the American Thoracic Society 9
• Crackles are most prevalent in lung bases initially, extending toward upper zones with disease progression, as reported by the American Thoracic Society 9
• An accentuated pulmonic second sound may be heard in advanced disease with pulmonary hypertension, as indicated by the American Thoracic Society 9

Differential Diagnoses

• Idiopathic pulmonary fibrosis (IPF) is the most common progressive ILD, typically in patients >50 years, male smokers, with UIP pattern on HRCT, as noted by the American Thoracic Society 9
• Connective tissue disease-associated ILD, particularly rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease, as reported by the American College of Rheumatology 10 and the European League Against Rheumatism 11
• Sarcoidosis is more common in young and middle-aged adults, granulomatous disease, according to the American Thoracic Society 9

Investigations

• Baseline FVC <80% has only 47.5% sensitivity for detecting ILD, emphasizing need for imaging, as noted by the American College of Rheumatology 12
• HRCT has 95.7% sensitivity and 63.8% specificity for detecting ILD with ≥20% lung involvement, as reported by the American College of Rheumatology 12
• Chest radiography alone is insufficient; up to 10% of ILD patients have normal chest X-rays, according to the American College of Chest Physicians 13
• HRCT should include inspiratory prone images and supine end-expiratory imaging, as recommended by the American College of Rheumatology 12
• Ambulatory desaturation testing every 3-12 months for monitoring, as suggested by the American College of Rheumatology 12

Management

• Baseline dyspnea is associated with increased mortality in ILD patients, as reported by the American Thoracic Society 14
• Do not attribute cough and dyspnea solely to ILD without excluding cardiac disease, asthma, and postnasal drainage, as noted by the American Thoracic Society 14 and the American Thoracic Society 15

Chronic Interstitial Lung Changes in Both Lower Lungs

Clinical Significance and Prognosis

• Individuals with interstitial lung abnormalities (ILAs) have a 66% increased risk of death compared to those without these abnormalities, with particularly elevated respiratory-specific mortality, according to the American Thoracic Society 16, 17
• More than half of patients with ILAs experience radiologic progression over 5 years, with associated clinical worsening including onset of respiratory symptoms and reduction in exercise capacity, as reported by the American Journal of Respiratory and Critical Care Medicine 16
• Approximately 10% of patients with ILAs progress to clinically significant interstitial lung disease (ILD) annually, though this varies based on the at-risk population and specific imaging characteristics, as stated by the American Thoracic Society 16
• Patients with radiologically progressive ILAs experience accelerated lung function decline, with a 64-ml annual decline in forced vital capacity (FVC) compared to 35-ml decline in those without ILAs, according to the American Thoracic Society 17

Symptom Profile

• Chronic cough occurs in 30.5% of patients with ILAs compared to 13.9% without, making it a frequent but not invariable presenting symptom, as reported by the American Thoracic Society 16
• Dyspnea on exertion affects 37.1% of patients with ILAs compared to 18.4% without, though up to 90% of early ILD cases may be asymptomatic, according to the American Thoracic Society 16

Underlying Causes to Investigate

• Connective tissue diseases, including rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, antisynthetase syndrome, mixed CTD, Sjögren's disease, or overlap syndrome, account for 25% of ILD cases, as stated by the American College of Rheumatology 18
• Smoking history is a major causative driver of ILAs/ILD when combined with genetic susceptibility, with approximately 8% of smokers undergoing lung cancer screening having ILAs/ILD, according to the American Thoracic Society 19
• Family history of pulmonary fibrosis is a risk factor, as 15-30% of asymptomatic first-degree relatives of patients with familial pulmonary fibrosis or sporadic IPF have ILAs on chest CT, as reported by the American Thoracic Society 16
• Occupational and environmental exposures, including mold and air pollution, interact with genetic susceptibility as causative drivers of ILAs/ILD, according to the American Thoracic Society 16

Mandatory Initial Workup

• All patients with bilateral lower lobe interstitial changes require baseline symptom assessment, including inquiry about cough and dyspnea on exertion, even if currently asymptomatic, as recommended by the American Thoracic Society 18, 20
• Baseline pulmonary function testing, including measurement of FVC, total lung capacity (TLC), and diffusion capacity (DLCO), is essential to establish a baseline for future comparison and identify early ILD, according to the American Thoracic Society 18, 20

Critical Pitfalls to Avoid

• Do not dismiss the finding as clinically insignificant even in asymptomatic patients, as ILAs are associated with increased mortality and progression risk regardless of symptoms, as stated by the American Thoracic Society 16

Guideline Recommendations for Evaluation and Management of Chronic Interstitial Lung Disease

Exposure Assessment

• Comprehensive documentation of environmental and occupational exposures (e.g., mold, air pollution, occupational vapors, gases, dusts, fumes) is essential for optimal outcomes in patients with suspected ILD, as these factors interact with genetic susceptibility to drive disease development. 21
• A family history of pulmonary fibrosis is significant: 15–30 % of first‑degree relatives of individuals with familial pulmonary fibrosis exhibit interstitial lung abnormalities on imaging. 21

Cardiovascular Evaluation

• Routine echocardiography is strongly recommended in the initial work‑up of ILD to identify structural cardiac or vascular anomalies; such anomalies are detected in up to 9 % of children evaluated for ILD. [22][23]
• The presence of pulmonary hypertension in ILD patients is associated with a worse prognosis, underscoring the need for early detection and management. [22][23]

Bronchoalveolar Lavage (BAL) Diagnostic Thresholds

• A lymphocyte differential count > 25 % in BAL fluid suggests granulomatous diseases (e.g., sarcoidosis, hypersensitivity pneumonitis, chronic beryllium disease), cellular NSIP, drug‑induced lung injury, or cryptogenic organizing pneumonia. 24
• A lymphocyte count > 50 % strongly points toward hypersensitivity pneumonitis or cellular NSIP. 24
• An eosinophil count > 25 % in BAL fluid is virtually diagnostic of acute or chronic eosinophilic pneumonia. 24
• A CD4⁺/CD8⁻ ratio > 4 in BAL fluid is highly specific for sarcoidosis when other inflammatory cell populations are not markedly increased. 24

Tissue Diagnosis

• Surgical lung biopsy should be considered in rapidly progressive ILD cases or when transbronchial lung cryobiopsy (TBLC) yields nondiagnostic results. [22][23]

Risk‑Reduction Strategies

• Smoking cessation is the single most effective intervention to slow ILD progression; a combined approach using pharmacotherapy (nicotine replacement, varenicline, or bupropion) and behavioral support is recommended. 21
• Removal or remediation of identified environmental, occupational, or medication triggers is advised to reduce ongoing lung injury. 21
• Age‑appropriate vaccinations (influenza and pneumococcal) are recommended to lower the risk of respiratory infections that can exacerbate ILD. 21

Follow‑Up and Monitoring

• Serial pulmonary function tests (spirometry and DLCO) should be performed every 3–6 months during the first year after diagnosis and annually thereafter if the disease remains stable. 21
• A repeat high‑resolution CT (HRCT) is recommended 2–3 years after the baseline scan to assess radiologic progression. 21
• In patients with high‑risk features (e.g., definite fibrosis, subpleural fibrotic pattern, extensive radiographic abnormalities, abnormal PFTs, family history of fibrosis, older age, or smoking history), an earlier HRCT at 12 months is appropriate. 21

Diagnosis and Management of Interstitial Lung Disease (ILD)

Diagnostic Evaluation

• A multidisciplinary approach that combines high‑resolution CT (HRCT), pulmonary function testing, and detailed clinical assessment is essential for a definitive ILD diagnosis. 25
• Fine “velcro” crackles on inspiration are present in > 80 % of patients with idiopathic pulmonary fibrosis (IPF). American Thoracic Society recommendation. 26
• Current or former smoking is a major risk factor and is found in the majority of IPF patients. American Thoracic Society recommendation. 26
• Routine measurement of serum biomarkers (MMP‑7, surfactant protein D, CCL‑18, KL‑6) is not recommended for differentiating IPF from other ILDs. American Thoracic Society recommendation. 26
• When HRCT shows a definite usual interstitial pneumonia (UIP) pattern, surgical lung biopsy, trans‑bronchial biopsy, or cryobiopsy is not indicated. American Thoracic Society recommendation. 26
• Broncho‑alveolar lavage (BAL) cellular analysis is not recommended in patients with a UIP pattern on HRCT. American Thoracic Society recommendation. 26
• Multidisciplinary discussion among pulmonologists, radiologists, and pathologists improves diagnostic accuracy and overall patient care. American Thoracic Society recommendation. 25
• Total lung capacity measurement confirms restrictive physiology in ILD. 25
• Diffusing capacity for carbon monoxide (DLCO) evaluates gas‑exchange impairment in ILD. 25

HRCT Radiologic Patterns

• Usual interstitial pneumonia (UIP) pattern: subpleural reticulation, traction bronchiectasis, honey‑comb cysts, basal‑peripheral distribution. ATS/ERS guideline. 27
• Non‑specific interstitial pneumonia (NSIP) pattern: ground‑glass opacities with reticulation and a more uniform distribution. ATS/ERS guideline. 27
• Early fibrotic changes (fine reticulation, intralobular lines, architectural distortion) are identifiable on HRCT. ATS/ERS guideline. 27

Treatment of Idiopathic Pulmonary Fibrosis (IPF)

• Antifibrotic therapy with nintedanib or pirfenidone reduces the annual decline in forced vital capacity (FVC) by approximately 44–57 % and should be started at the time of diagnosis. ATS/ERS guideline. 27
• Both nintedanib and pirfenidone have comparable efficacy in slowing disease progression. ATS/ERS guideline. 27

Management of Progressive Fibrosing ILD (PF‑ILD)

• PF‑ILD is defined by at least two of the following within 12 months (without an alternative explanation):
• Antifibrotic therapy with nintedanib or pirfenidone is recommended for PF‑ILD regardless of the underlying ILD subtype. ATS/ERS guideline. 27, 28

Non‑pharmacologic Interventions

• Structured pulmonary rehabilitation improves six‑minute walk distance and health‑related quality of life. ATS/ERS guideline. 27
• Supplemental oxygen for patients desaturating < 88 % during a six‑minute walk reduces dyspnea and enhances quality of life. ATS/ERS guideline. 27

Monitoring and Follow‑up

• Patients should be evaluated every 3–6 months to detect disease progression. ATS/ERS guideline. 27
• Follow‑up HRCT is indicated when clinical worsening is suspected and should be performed annually for cancer surveillance. ATS/ERS guideline. 27, 29
• In high‑risk individuals (definite fibrosis, extensive radiographic abnormalities, abnormal pulmonary function, first‑degree family history, older age, or smoking), an earlier HRCT at 12 months is advisable. ATS/ERS guideline. 29

Lung Transplant Referral

• Patients with an elevated risk of mortality should be referred for lung transplantation at the time of diagnosis. ATS/ERS guideline. 27

Acute Exacerbations

• Acute exacerbations of ILD are treated with systemic corticosteroids. ATS/ERS guideline. 27
• Routine invasive mechanical ventilation is not recommended for most patients with respiratory failure due to ILD. ATS/ERS guideline. 27

Comorbidity Assessment

• Systematic evaluation and treatment of gastro‑esophageal reflux disease, obstructive sleep apnea, and lung cancer are recommended as part of ILD management. ATS/ERS guideline. 27

Biopsy Strategies and Multidisciplinary Diagnosis in Interstitial Lung Disease

Biopsy Indications and Preferred Techniques

• In patients with suspected interstitial lung disease (ILD) whose high‑resolution CT (HRCT) and clinical assessment do not yield a definitive diagnosis, a lung tissue biopsy should be considered. The European Respiratory Society recommends proceeding to tissue sampling when non‑invasive evaluation is inconclusive 30.

• Transbronchial lung cryobiopsy (TBLC) is suggested as the first‑line biopsy method for obtaining histopathological confirmation in such cases, because it provides larger specimens with fewer crush artifacts and carries a lower complication rate than surgical lung biopsy. Strength of evidence: moderate (expert consensus and comparative series) 30.

• Surgical lung biopsy (via video‑assisted thoracoscopic surgery, VATS) should be reserved for rapidly progressive ILD or when TBLC results are nondiagnostic. Strength of evidence: moderate 30.

Diagnostic Yield Comparison

Multidisciplinary Discussion (MDD) Framework

• After integrating clinical data, HRCT patterns, and biopsy results, a multidisciplinary discussion involving pulmonologists, radiologists, and pathologists is mandatory to reach a final diagnosis. Strength of evidence: high (guideline recommendation) 30.

• The MDD categorises diagnostic confidence into four tiers:

  These tiers guide subsequent management and follow‑up planning 30.

Diagnostic and Management Recommendations for Fine Inspiratory Crackles in Interstitial Lung Disease

Acoustic Characteristics

Immediate Imaging

Clinical Evaluation Pitfalls

Functional Assessment

Multidisciplinary Diagnostic Process

Guideline Recommendations for Interstitial Lung Disease (ILD) Diagnosis and Management

Diagnostic Approach

• High‑Resolution CT (HRCT) is the gold‑standard imaging test for suspected ILD and achieves 95.7 % sensitivity for disease involving ≥20 % of lung parenchyma, even in asymptomatic patients. 34
• Fine, dry “Velcro‑type” end‑inspiratory crackles are heard in >80 % of idiopathic pulmonary fibrosis (IPF) patients, but the finding has only moderate sensitivity for early disease. 35
• Up to 90 % of patients with early rheumatoid‑arthritis‑associated ILD have no dyspnea or cough; absence of symptoms does not rule out disease. 34

HRCT Imaging Protocol

• HRCT acquisition should include inspiratory prone and supine end‑expiratory images with slice thickness ≤2 mm and axial contiguous or non‑reconstructed slices spaced ≤2 cm. 36
• Honeycombing is mandatory to label a pattern as definite usual interstitial pneumonia (UIP) on HRCT. 37
• Prominent diffuse ground‑glass attenuation or mosaic‑pattern ground‑glass attenuation are features that argue against a UIP pattern. 36

Tissue Diagnosis Strategy

• When HRCT demonstrates a definite UIP pattern in the appropriate clinical context, further invasive sampling (surgical lung biopsy, transbronchial biopsy, or cryobiopsy) is not indicated. 35

Multidisciplinary Discussion (MDD)

• A formal multidisciplinary discussion involving pulmonologists, radiologists, and pathologists experienced in ILD is mandatory to integrate clinical, radiologic, and pathologic data for optimal diagnostic accuracy. [35][34]36
• Complex or ambiguous cases should be referred to expert ILD centers or specialized pulmonology departments. 36

Prognostic Assessment (IPF)

• Prognosis at diagnosis should be based on: These factors are recommended for risk stratification with strong evidence.* 38

Therapeutic Recommendations – Treatments to Avoid

• Triple therapy with prednisone, azathioprine, and N‑acetylcysteine is contraindicated in patients with a definite IPF diagnosis; this is a strong recommendation against its use. [36][38]

Definition and Management of Progressive Pulmonary Fibrosis (PPF)

• PPF is defined by the presence of at least two of the following within 12 months, without an alternative explanation: All three criteria are supported by evidence.* 34

Monitoring and Follow‑Up

• Serial pulmonary function tests (spirometry and DLCO) should be performed every 3–6 months during the first year after diagnosis to detect progression. 34
• A follow‑up HRCT is recommended 2–3 years after the baseline scan to assess radiologic progression; earlier HRCT (at 12 months) is advised for high‑risk patients (e.g., definite fibrosis, extensive radiographic abnormalities, abnormal PFTs, family history, older age, or smoking). 34

Additional Diagnostic Considerations

• Bronchoscopy, surgical lung biopsy, or cryobiopsy are not recommended for the diagnosis of connective‑tissue‑disease‑associated ILD according to current expert consensus. 34

Evidence‑Based Pharmacologic Recommendations for Interstitial Lung Disease (ILD)

Connective‑Tissue‑Disease‑Associated ILD (CTD‑ILD)

• Mycophenolate is recommended as the preferred first‑line immunosuppressive agent for adult patients with CTD‑ILD, based on consensus guidance from rheumatology societies. This recommendation is conditional and reflects expert opinion that mycophenolate improves lung function and quality of life in this population. [39][40]

• Azathioprine, rituximab, and cyclophosphamide are listed as alternative first‑line options for CTD‑ILD when mycophenolate is contraindicated or not tolerated. These agents have been endorsed by the same rheumatology guideline panel. 40

• Rituximab may be selected as the initial therapy for rheumatoid arthritis‑associated ILD with active inflammatory arthritis, because it is associated with reduced mortality and may limit ILD progression by controlling systemic disease activity. This is a conditional recommendation. 39

• Short‑term glucocorticoids can be used as a bridge therapy in CTD‑ILD (excluding systemic sclerosis‑ILD), but long‑term use is discouraged due to toxicity. The guidance emphasizes a limited course (≤ 3 months) before transitioning to a steroid‑sparing agent. [39][40]

Systemic‑Sclerosis‑Associated ILD (SSc‑ILD)

• Glucocorticoids are conditionally advised against as first‑line therapy for SSc‑ILD because of a documented risk of precipitating scleroderma renal crisis. This recommendation is based on safety concerns rather than efficacy data. [39][40]

• First‑line disease‑modifying options for SSc‑ILD include mycophenolate, azathioprine, rituximab, cyclophosphamide, tocilizumab, and the antifibrotic nintedanib. These agents are supported by expert consensus as having favorable risk‑benefit profiles in this subgroup. 40

Idiopathic Inflammatory Myopathy‑Associated ILD (IIM‑ILD)

• Mycophenolate, azathioprine, rituximab, cyclophosphamide, Janus‑kinase (JAK) inhibitors, and calcineurin inhibitors are endorsed as first‑line therapeutic choices for adult patients with IIM‑ILD. The recommendation is conditional, reflecting limited high‑quality trial data. 40

Medications to Avoid or Discontinue in ILD

• Leflunomide, methotrexate, tumor‑necrosis‑factor (TNF) inhibitors, and abatacept are conditionally recommended against as first‑line treatments for any ILD subtype. This reflects concerns about potential pulmonary toxicity. 40

• If ILD develops while a patient is receiving any of the above agents, some guideline panelists suggest stopping the offending medication. This is a conditional recommendation. 39

• Pirfenidone is conditionally advised against as a first‑line agent for systemic‑autoimmune‑related ILD (SARD‑ILD). The guidance is based on limited efficacy data in this context. 40

• Adding nintedanib or pirfenidone to mycophenolate in patients already receiving mycophenolate, without evidence of ILD progression, is conditionally discouraged. This recommendation aims to avoid unnecessary polypharmacy and potential adverse effects. 40

Co‑Management and Shared Decision‑Making

• Initiation of ILD pharmacotherapy should be co‑managed by pulmonologists and rheumatologists to ensure appropriate patient selection, especially for asymptomatic individuals with mild disease. This collaborative approach is endorsed by rheumatology guideline societies. 39

• Because most therapeutic recommendations are conditional, shared decision‑making that incorporates disease severity, progression risk, comorbidities, cost, and toxicity is essential when selecting a medication regimen. This patient‑centered strategy aligns with the guideline panel’s emphasis on individualized care. 39